Eveline Chen
Overview
Explore the profile of Eveline Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metzger Filho O, Ballman K, Campbell J, Liu M, Ligibel J, Watson M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401875.
PMID: 39746162
Purpose: In light of evolving evidence that some patients with node-positive estrogen receptor-positive (ER+) disease may receive less benefit from chemotherapy, this study reports 12-year outcomes of the C9741 trial...
2.
Sura G, Tran K, Fu C, Du L, Marczyk M, Gould R, et al.
Cytopathology
. 2023 Sep;
34(6):551-561.
PMID: 37712171
Objectives: To investigate the pre-analytics of the molecular testing of cytology specimens, we studied the effects of time in refrigerator storage (4°C) of malignant effusions on RNA sequencing (RNAseq) results....
3.
Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, et al.
Clin Chem
. 2020 Jul;
66(7):934-945.
PMID: 32613237
Background: We translated a multigene expression index to predict sensitivity to endocrine therapy for Stage II-III breast cancer (SET2,3) to hybridization-based expression assays of formalin-fixed paraffin-embedded (FFPE) tissue sections. Here...
4.
Mitra A, Andrews M, Roh W, De Macedo M, Hudgens C, Carapeto F, et al.
Nat Commun
. 2020 Apr;
11(1):1839.
PMID: 32296058
Complex tumor microenvironmental (TME) features influence the outcome of cancer immunotherapy (IO). Here we perform immunogenomic analyses on 67 intratumor sub-regions of a PD-1 inhibitor-resistant melanoma tumor and 2 additional...
5.
Reuben A, Spencer C, Prieto P, Gopalakrishnan V, Reddy S, Miller J, et al.
NPJ Genom Med
. 2017 Aug;
2.
PMID: 28819565
Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response has not been thoroughly elucidated. To better understand this, we studied...
6.
Roh W, Chen P, Reuben A, Spencer C, Prieto P, Miller J, et al.
Sci Transl Med
. 2017 Mar;
9(379).
PMID: 28251903
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms of resistance remain incompletely understood. To address this, we recently studied...